The effectiveness of this shelf, combined with two prior effective S-3s, creates a persistent dilution overhang. Monitor for any takedown announcements or registration statements that specify pricing, a large secondary could pressure the stock significantly given the small market cap.
KALA drugs
KALA drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 26 $2.52entry
- T+1 · 5mo ago −17.06%α −18.71% · $2.09
- T+5 · 4mo ago −33.33%α −35.50% · $1.68
- T+20 · 4mo ago −75.78%α −77.04% · $0.6103
- T+60 · 8w ago −77.78%α −82.26% · $0.5600
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
KALA BIO's shelf registration (File No. 333-295667) became effective on June 25, 2026, allowing the company to conduct offerings at any time. The underlying S-3 covers the resale of up to 241,435,910 shares of common stock by selling stockholders, primarily from preferred stock conversions and settlement agreements. This creates a substantial potential dilution overhang for a $47M market cap company.
Key Facts
- Shelf registration effective June 25, 2026, under File No. 333-295667.
- Covers resale of up to 241,435,910 shares of common stock by selling stockholders.
- Shares include 12,000,010 Series AA conversion shares, 226,335,900 Series AAA conversion shares, 2,200,000 LifeSci settlement shares, and 900,000 Baker settlement shares.
- Market cap is approximately $47M, making the potential dilution massive relative to current float.
- Two prior S-3 filings (Feb 2026 and May 2026) also went effective, compounding the overhang.
Financial Impact
Potential dilution of up to 241.4M shares against a $47M market cap; no specific offering amount or pricing disclosed.
Risk Factors
- Massive potential dilution from up to 241.4M registered shares relative to current float.
- Multiple effective shelves increase the risk of near-term offerings.
- Selling stockholders include large holders (Baker Bros., LifeSci) who may seek to exit.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002122 |
| Document: 9999999995-26-002122-index.html | 9999999995-26-002122 |
| Document: 9999999995-26-002122.txt | 9999999995-26-002122 |
Track record
10 reports on KALA
2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +68.51% at T+60 after the Jul 22, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.1496 Now $0.1390 +7.09% settles Nov 17
- Nov 12, 20264d ago 8-K Bearish 5/10 Entry $0.1388 to $0.1277 Now $0.1390 −0.14% ▲ +8.02% +6.11% vs SPY
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1773 to $0.1710 Now $0.1390 −21.60% ▼ −3.55% −3.19% vs SPY
- Oct 19, 202628d ago SC 13G Neutral 3/10 Entry $0.1926 to $0.1897 Now $0.1390 −27.83% ▼ −1.51% −1.84% vs SPY
- Sep 24, 20267w ago Press Release Neutral 3/10 Entry $0.5600 to $0.4760 Now $0.1390 −75.18% ▼ −15.00% −15.54% vs SPY
- Aug 28, 202611w ago 8-K Bearish 8/10 Entry $0.6901 to $0.6727 Now $0.1390 +79.86% ▲ +2.52% +2.22% vs SPY
- Jul 22, 202616w ago 424B5 Bearish 8/10 Entry $0.6103 to $0.6342 Now $0.1390 +77.22% ▼ −3.92% −3.81% vs SPY
- Jun 26, 202620w ago EFFECT Bearish 7/10 Viewing Entry $2.52 to $2.09 Now $0.1390 +94.48% ▲ +17.06% +18.71% vs SPY
- May 7, 202627w ago S-3 Neutral 2/10 Entry $3.95 to $3.91 Now $0.1390 −96.48% ▼ −1.01% −1.24% vs SPY
- Mar 4, 202636w ago Press Release Mixed 6/10 Entry $17.25 to $0.2750 Now $0.1390 −99.19% ▼ −98.41% −97.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers